Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
1/3/2024 | Buy → Hold | Needham | |
11/8/2023 | Outperform → Mkt Perform | Raymond James | |
7/18/2023 | $205.00 → $120.00 | Buy → Hold | Stifel |
7/10/2023 | $173.00 | Equal Weight | Wells Fargo |
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
Politan Will Take All Necessary Action to Ensure That the Annual Meeting Is Not Delayed Any Further Beyond September 19 and Hopefully Is Held Sooner Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today responded to the Company's Board of Directors moving Masimo's Annual Meeting of Stockholders (the "Annual Meeting"), previously scheduled for July 25, 2024, to September 19, 2024. Politan also commented on the Board bringing a lawsuit in federal court against Politan and its founder and CIO Quentin Koffey. Mr. Koffey is also a member of the Masimo Board. Mr. Koffey stated: "On Mon
Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that it has commenced litigation against Politan Capital Management LP ("Politan") in federal court in California seeking to require Politan to correct material misstatements and omissions in Politan's proxy materials. The complaint alleges, among other things, that Quentin Koffey has assisted plaintiff's counsel in litigation against Masimo. Masimo has also set a new date for its 2024 Annual Meeting of Stockholders (the "Annual Meeting") and a new record date to ensure that the vote of the Company's stockholders is fair and fully informed.
Both Leading Proxy Advisory Firms – ISS and Glass Lewis – Have Now Strongly Validated Politan's Case for Change and Recommended Shareholders Vote for Darlene Solomon and William Jellison in Order To Provide Urgently Needed Independent Oversight on Masimo's Board ISS Highlights the "Dangerous Lack of Accountability" on the Current Board and Notes That Mr. Kiani Has "No Regard for Public Shareholders" Concludes That Shareholders Have "No Reason to Believe Management Can Be Trusted" to Structure the "Pivotal" Separation of the Consumer Business, and That Change Is "Absolutely Necessary" To Ensure the Separation Does Not Harm Shareholder Value Dismisses Masimo's "Defensive Rhetoric That R
To ensure that Politan lies repeated over and over are not taken as fact, Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) sets forth below facts in response to what we believe are some of Politan's and Quentin Koffey's most egregious and continuing misrepresentations. These misrepresentations include Politan's and Mr. Koffey's continuing efforts to sow mistrust and confusion regarding the proposed consumer joint venture. In response, Masimo CEO Joe Kiani has committed that he will not support the proposed joint venture unless the entire Board, including Mr. Koffey, also supports it. We encourage our stockholders to vote FOR Joe Kiani and Christopher Chavez using the GOLD pr
First Quarter 2024 Highlights: Consolidated revenue was $492.8 million; Healthcare revenue was $339.6 million; Non-healthcare revenue was $153.2 million; GAAP net income per diluted share was $0.35; and Non-GAAP net income per diluted share was $0.77. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 50,400. Consolidated GAAP o
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call wi
Fourth Quarter 2023 Highlights: Consolidated revenue was $548.9 million; Healthcare revenue was $339.9 million; Non-healthcare revenue was $209.0 million; GAAP net income per diluted share of $0.63; and Non-GAAP net income per diluted share (updated definition) of $1.25. Full-Year 2023 Highlights: Consolidated revenue was $2,048.1 million; Healthcare revenue was $1,275.5 million; Non-healthcare revenue was $772.6 million. GAAP net income per diluted share of $1.51; and Non-GAAP net income per diluted share (updated definition) of $3.79. Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.
Complete fourth quarter and full-year 2023 financial results will be announced on Tuesday, February 27, 2024 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance. Preliminary Fourth Quarter 2023 Financial Results: • Consolidated revenue of $541 million to $551 million; • Healthcare revenue of $336 million to $341 million; and • Non-healthcare revenue of $205 million to $210 million. Preliminary Full-Year 2023 Financial Results: •
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Bob Chapek Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Bob Chapek has been appointed to Masimo's Board of Directors. Mr. Chapek was Chief Executive Officer of The Walt Disney Company, one of the world's largest media and entertainment companies, from February 2020 to November 2022, successfully leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and global reach of its streaming services, made transformative changes to its parks and resorts worldwide, and leveraged new and innovative technologies to bring stories to life in more immer
Rolf A. Classon Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Rolf A. Classon has been appointed to Masimo's Board of Directors. Mr. Classon is an experienced medical technology executive and board member. From October 2002 until his retirement in July 2004, he was Chairman of the Executive Committee of Bayer HealthCare AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon has served as Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since 2011,
Vote the WHITE Proxy Card Today Visit KeepMasimoStrong.com for More Information The Board of Directors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today issued a letter to stockholders in connection with the Company's Annual Meeting of Stockholders to be held on June 26, 2023. To protect stockholders' investment and to ensure Masimo continues to innovate breakthrough solutions to help improve lives, improve patient outcomes and reduce cost of care, and take noninvasive monitoring to new sites and applications, the Board encourages stockholders to vote FOR Masimo's highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Your vote on the WHITE pro
- Reuters Citing CNBC
Highlights Quentin Koffey's Actions That Have Flown in the Face of Good GovernanceMasimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numerous actions Politan has taken to advance its own agenda at the expense of Masimo's governance and stockholder value.
Masimo Corporation (NASDAQ:MASI) shares are trading lower on Tuesday. Yesterday, Masimo reportedly disclosed that a potential joint venture partner is poised to bid between $850 million and $950 million for its consumer business encompassing health and audio products, reported Reuters. Masimo is currently engaged in active discussions with this unnamed partner regarding the joint venture terms, including Masimo’s proposal to manage ongoing litigation outcomes with Apple Inc. (NASDAQ:AAPL). Also Read: Masimo CEO ‘Wholeheartedly’ Feels Apple Watch Users Are Better Off Without Blood Oxygen Monitoring Feature Today, the company disclosed the preliminary results for the second quarter
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
Stifel upgraded Masimo from Hold to Buy and set a new price target of $170.00 from $148.00 previously
Wells Fargo upgraded Masimo from Equal Weight to Overweight and set a new price target of $160.00 from $117.00 previously
Jefferies downgraded Masimo from Buy to Hold and set a new price target of $121.00 from $107.00 previously